A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This is a multicenter, open label extension study. Subjects who have completed treatment in the parent study of pertuzumab, either alone or with a combination agent, and who received at least one dose of pertuzumab in the parent study are eligible for inclusion in this trial if they are continuing to receive clinical benefit.
Epistemonikos ID: 2a0152fd5f6414430fb6d15ce379a6af3f4d12d3
First added on: May 04, 2024